<DOC>
	<DOCNO>NCT00469586</DOCNO>
	<brief_summary>This trial conduct Europe , Asia , North America South America . The aim research trial compare efficacy inhaled insulin glimepiride metformin combination therapy treatment subject type 2 diabetes verify safety use ( hypoglycaemia , pulmonary function , body weight , insulin antibody side effect ) .</brief_summary>
	<brief_title>Efficacy Safety Inhaled Insulin Compared Metformin Glimepiride Type 2 Diabetes</brief_title>
	<detailed_description>The decision discontinue development AERxÂ® due safety concern . An analysis conclude fast-acting inhaled insulin form know today , unlikely offer significant clinical convenience benefit injection modern insulin pen device .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes Treated OADs equal 3 month HbA1c great equal 8.0 % less equal 11.0 % Body Mass Index ( BMI ) less equal 40.0 kg/m2 Recurrent major hypoglycaemia Current smoking smoking within last 6 month Impaired hepatic renal function Cardiac problem Uncontrolled hypertension Proliferative retinopathy maculopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>